Ken Griffin Citadel Advisors
Ken Griffin founded Citadel, one of the world’s largest and most successful hedge funds. Starting his trading career from his Harvard dorm room at a young age, Griffin quickly developed a keen sense for markets and built Citadel into a global powerhouse with billions in assets under management. Known for his quantitative and technology-driven strategies, Griffin has also made headlines for significant philanthropic contributions, supporting causes in education, the arts, and public institutions. Over the years, he has earned recognition as one of the preeminent figures in modern finance.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Core S&P 500 ETF
IVV
|
+$1.16B |
| 2 |
Uber
UBER
|
+$452M |
| 3 |
Analog Devices
ADI
|
+$421M |
| 4 |
Walt Disney
DIS
|
+$376M |
| 5 |
Alphabet (Google) Class A
GOOGL
|
+$375M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$1.55B |
| 2 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$1.08B |
| 3 |
Bristol-Myers Squibb
BMY
|
+$430M |
| 4 |
NVIDIA
NVDA
|
+$368M |
| 5 |
JPMorgan Chase
JPM
|
+$365M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 3.78% |
| 2 | Healthcare | 3.27% |
| 3 | Industrials | 2.02% |
| 4 | Financials | 2.02% |
| 5 | Consumer Discretionary | 1.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3801
CALL
Microvision
MVIS
$53M
| $4.29M | ﹤0.01% |
53,220
+44,927
| +542% | +$1.98M |
|
3802
Karyopharm Therapeutics
KPTI
$45.8M
| $4.29M | ﹤0.01% |
18,472
-43,357
| -70% | -$10M |
|
|
KYNB
3803
CALL
Kyntra Bio
KYNB
$28.5M
| $4.28M | ﹤0.01% |
4,620
+2,776
| +151% | +$2.92M |
|
3804
CALL
Watsco Inc
WSO
$12.9B
| $4.28M | ﹤0.01% |
18,900
-5,700
| -23% | -$1.31M |
|
|
LOGC
3805
PUT
DELISTED
ContextLogic
LOGC
| $4.28M | ﹤0.01% |
+7,820
| New | +$4.83M |
|
3806
CALL
Beam Therapeutics
BEAM
$2.76B
| $4.28M | ﹤0.01% |
+52,400
| New | +$2.58M |
|
3807
PUT
Direxion Daily FTSE China Bull 3X ETF
YINN
$653M
| $4.27M | ﹤0.01% |
10,590
+1,235
| +13% | +$463K |
|
3808
Usana Health Sciences
USNA
$247M
| $4.27M | ﹤0.01% |
55,398
+8,071
| +17% | +$624K |
|
3809
National Vision
EYE
$1.53B
| $4.27M | ﹤0.01% |
94,238
+72,511
| +334% | +$3.15M |
|
3810
ProShares UltraShort S&P500
SDS
$372M
| $4.27M | ﹤0.01% |
+13,776
| New | +$4.84M |
|
|
BCPC
3811
Balchem Corp
BCPC
$5.69B
| $4.27M | ﹤0.01% |
37,032
-3,963
| -10% | -$418K |
|
|
RWT
3812
CALL
Redwood Trust
RWT
$604M
| $4.27M | ﹤0.01% |
485,900
+359,800
| +285% | +$3.09M |
|
|
GAN
3813
PUT
DELISTED
GAN Ltd
GAN
| $4.26M | ﹤0.01% |
210,200
+106,600
| +103% | +$1.79M |
|
|
SUMO
3814
CALL
DELISTED
Sumo Logic, Inc. Common Stock
SUMO
| $4.26M | ﹤0.01% |
+149,100
| New | +$3.51M |
|
3815
WisdomTree Emerging Markets High Dividend Fund
DEM
$3.97B
| $4.26M | ﹤0.01% |
103,470
-49,586
| -32% | -$1.9M |
|
3816
CALL
Calix
CALX
$2.49B
| $4.26M | ﹤0.01% |
143,000
+81,300
| +132% | +$2.01M |
|
3817
CALL
Huntington Bancshares
HBAN
$36.2B
| $4.25M | ﹤0.01% |
336,900
+800
| +0.2% | +$9.09K |
|
3818
Pentair
PNR
$10.6B
| $4.25M | ﹤0.01% |
80,130
-413,772
| -84% | -$21.2M |
|
|
CXO
3819
PUT
DELISTED
CONCHO RESOURCES INC.
CXO
| $4.25M | ﹤0.01% |
72,900
-93,600
| -56% | -$4.93M |
|
3820
CALL
Guidewire Software
GWRE
$14.6B
| $4.25M | ﹤0.01% |
33,000
-3,700
| -10% | -$422K |
|
3821
iShares Preferred and Income Securities ETF
PFF
$13.3B
| $4.24M | ﹤0.01% |
+110,144
| New | +$4.12M |
|
3822
PUT
Vanguard FTSE Europe ETF
VGK
$31.1B
| $4.24M | ﹤0.01% |
70,400
+16,000
| +29% | +$901K |
|
|
DAY
3823
CALL
DELISTED
Dayforce
DAY
| $4.24M | ﹤0.01% |
39,800
+18,900
| +90% | +$1.79M |
|
|
ONC
3824
PUT
BeOne Medicines Ltd
ONC
$39.3B
| $4.24M | ﹤0.01% |
16,400
+9,200
| +128% | +$2.53M |
|
3825
Advantage Solutions
ADV
$420M
| $4.24M | ﹤0.01% |
+12,865
| New | +$3.38M |
|
Similar funds
Ken Griffin's Q4 2020 Portfolio in Review
As of Q4 2020, Ken Griffin held 11,975 positions worth $385B, up 9.1% from $353B the previous quarter. Its ten largest holdings account for 31% of the portfolio.
Ken Griffin withdrew a net $35.1B in Q4 2020, closing 1,130 positions and reducing 4,218 holdings. Its most notable exit was Immunomedics Inc, an estimated $213M position sold in full.
By sector, the portfolio is most concentrated in Technology at 3.8% of assets, up from 3% a quarter earlier, followed by Healthcare and Industrials.
Against the trend, Ken Griffin opened a new position in S&P Global worth $114M.
- Ken Griffin's largest Q4 2020 buy was S&P Global: 345,785 shares worth $114M.
- Ken Griffin added most to iShares Core S&P 500 ETF in Q4 2020, an estimated $1.16B increase.
- Ken Griffin's biggest Q4 2020 reduction was Amazon, cutting an estimated $1.55B.
- Ken Griffin fully exited Immunomedics Inc in Q4 2020, selling an estimated $213M.
- Ken Griffin's ten largest holdings make up 31% of its $385B portfolio in Q4 2020.
- Ken Griffin opened 1,988 new positions and closed 1,130 in Q4 2020.
- Ken Griffin's portfolio value rose 9.1% quarter-over-quarter to $385B.
Based on Citadel Advisors's 13F filing for Q4 2020, filed 16 Feb 2021.